Holen Sie sich die Stockscreener-App
251.06
0.23%
-0.58
Handel nachbörslich:
251.00
-0.06
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$251.64
Offen:
$250.75
24-Stunden-Volumen:
6.87M
Relative Volume:
0.99
Marktkapitalisierung:
$443.57B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
123.83
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
+6.88%
1M Leistung:
+17.91%
6M Leistung:
+9.88%
1J Leistung:
+32.14%
1-Tages-Spanne:
$247.56
$251.80
1-Wochen-Bereich:
$233.66
$255.99
52-Wochen-Spanne:
$184.63
$255.99
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
251.06 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,191.74 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.98 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
125.37 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.14 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Stock: Apogee Deal Just Widened An Already Dominant Moat (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment - Yahoo Finance
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today - Benzinga
RBC Capital reiterates Abbvie stock Outperform rating at $260 By Investing.com - Investing.com Canada
Galderma Slumps After FDA Turns Down Botox Rival Relfydess - The Business of Fashion
AbbVie (ABBV) Shares Dip After Six-Day Surge Amid $10.9B Acquisi - GuruFocus
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? - The Motley Fool
AbbVie shares fell after six-session winning streak - MSN
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
ABBVAbbvie Inc Latest SEC Filings - Finviz
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week? - TradingView
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Benzinga
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Yahoo! Finance Canada
US lawmakers probe Merck and AbbVie China clinical trials - grafa.com
AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk - Moomoo
STIFEL FINANCIAL CORP's AbbVie Inc(ABBV) Holding History - GuruFocus
Why is AbbVie stock slipping today? By Investing.com - Investing.com Canada
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck, AbbVie investigated over China military hospital drug trials - Yahoo Finance
AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China - marketscreener.com
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trials - Yahoo! Finance Canada
US House committee opens investigation into Merck, AbbVie China drug trials - marketscreener.com
Nxera reaches fourth R&D milestone under AbbVie accord - The Pharma Letter
AbbVie Stock 6-Day Winning Spree: Stock Climbs 17% - Trefis
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - marketscreener.com
Nxera Pharma Co LtdNxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases - TradingView
Big Pharma Has a Case of Merger Mania - The Motley Fool
AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying? - NAI500
AbbVie (ABBV) Reports Positive Results for Epkinly in Lymphoma T - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3 Trial Results for DLBCL T - GuruFocus
Juvederm Users Say AbbVie Hid Risks Of Filler - Law360
Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - marketscreener.com
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan
AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore
What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe - Yahoo Finance
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - Yahoo Finance
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $298 - Moomoo
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
ABBV Gains Traction as CHMP Recommends Upadacitinib for Alopecia Areata - GuruFocus
AbbVie Stock Surges 17%, With A 5-Day Winning Spree - Trefis
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Investing News Network
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - Investing News Network
AbbVie gets positive EU opinion for vitiligo treatment By Investing.com - Investing.com Canada
AbbVie’s upadacitinib receives positive EU opinion for alopecia By Investing.com - Investing.com Canada
AbbVie Inc.(NYSE: ABBV) added to Russell 1000 Value Benchmark - marketscreener.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Yahoo Finance
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):